P/FCF Ratio for Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN) P/FCF ratio is 16.5× as of June 5, 2026. The 5-year average is 20.0×. The sector median currently stands at 19.8×. The current ratio is at the 28th percentile of its own 10-year history.

Regeneron Pharmaceuticals (REGN) historical P/FCF ratio has ranged from a low of 7.8× (2022) to a high of 1179.8× (2010) in the available daily series.

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.